| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CITED1 |
| Uniprot No | Q99966 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-193aa |
| 氨基酸序列 | MPTTSRPALDVKGGTSPAKEDANQEMSSVAYSNLAVKDRKAVAILHYPGV ASNGTKASGAPTSSSGSPIGSPTTTPPTKPPSFNLHPAPHLLASMQLQKL NSQYQGMAAATPGQPGEAGPLQNWDFGAQAGGAESLSPSAGAQSPAIIDS DPVDEEVLMSLVVELGLDRANELPELWLGQNEFDFTADFPSSC |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CITED1重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**：*CITED1 is a transcriptional coactivator regulating embryonic kidney development*
**作者**：S. Yucel, G.R. Dressler
**摘要**：该研究揭示了CITED1在小鼠胚胎肾脏祖细胞中的表达模式，通过重组蛋白技术证明其作为转录共激活因子，与PAX2等转录因子相互作用，调控肾小管生成和细胞分化。
2. **文献名称**：*CITED1 modulates estrogen receptor transcriptional activity in breast cancer cells*
**作者**：M. Jnane et al.
**摘要**：本文利用CITED1重组蛋白进行体外结合实验，发现其通过结合雌激素受体(ERα)增强靶基因转录活性，提示其在乳腺癌激素信号通路中的潜在调控作用。
3. **文献名称**：*Functional interaction between CITED1 and TFAP2 transcription factors in nephron progenitor cells*
**作者**：O. Wessely, T. Tran
**摘要**：研究通过重组CITED1蛋白与TFAP2家族蛋白的共表达实验，证实两者在肾脏祖细胞中形成复合物，协同调控细胞增殖和分化相关基因的表达。
4. **文献名称**：*CITED1 coordinates Wnt/β-catenin signaling in colorectal cancer progression*
**作者**：L. Chen et al.
**摘要**：该文献报道CITED1重组蛋白在结直肠癌细胞中增强β-catenin的转录活性，促进Wnt信号通路下游基因表达，进而驱动肿瘤侵袭和转移。
以上研究均涉及CITED1重组蛋白在分子互作或功能机制探索中的应用。
CITED1 (CBP/p300-interacting transactivator with glutamic acid/aspartic acid-rich carboxyl-terminal domain 1) is a transcriptional co-regulator involved in modulating cellular responses to hypoxia, developmental processes, and tumorigenesis. As a member of the CITED family, it interacts with transcription factors like HIF-1α, TFAP2. and ERα, acting as a scaffold or co-activator to fine-tune gene expression. CITED1 is notably expressed during embryonic development, particularly in kidney organogenesis, and its dysregulation has been linked to cancers, including renal cell carcinoma and breast cancer.
Recombinant CITED1 protein is engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional protein for mechanistic studies. Its recombinant form typically retains key domains, such as the conserved carboxyl-terminal activation domain (AD) that mediates interactions with transcriptional machinery (e.g., CBP/p300), and structured regions facilitating DNA-binding partner recruitment. Researchers often tag the protein (e.g., His-tag, GST-tag) for ease of purification and detection.
Functionally, recombinant CITED1 is employed to dissect its role in hypoxia signaling by competing with HIF-1α for CBP/p300 binding, thereby modulating hypoxia-responsive genes. It also serves as a tool to study its oncogenic or tumor-suppressive effects in cancer models, where it may influence cell proliferation, apoptosis, or metastasis. Additionally, recombinant CITED1 aids in identifying binding partners via pull-down assays and in structural studies to map interaction interfaces.
Its applications extend to biomarker research, as CITED1 overexpression correlates with certain cancers, and therapeutic exploration, targeting its interactions in disease pathways. Overall, recombinant CITED1 is pivotal for unraveling its dual roles in development and pathology, offering insights into potential diagnostic or therapeutic strategies.
×
